Prajakta A. Sonalker

Prajakta A. Sonalker, Ph.D.


Associate, New York

Prajakta Sonalker, Ph.D., focuses her practice on patent litigation with an emphasis on pharmaceutical and biotechnology patent litigation.

Prajakta is a registered patent attorney with several years of experience in biotechnology, pharmaceutical, chemical and medical device patent prosecution, patentability assessments, inventorship analyses, and intellectual property due diligence for licensing and business development activities. She has also been involved in interference, opposition, re-examination, and patent infringement and litigation proceedings.

Prior to joining the firm, she worked as the Intellectual Property Manager for New York University where she supervised the preparation, prosecution and maintenance of NYU’s extensive patent portfolio, and as a technical specialist for Human Genome Sciences, Inc., a leading biotechnology company in the Washington D.C metro area.

Prajakta received her Ph.D. in Molecular Pharmacology in 2006 from the University of Pittsburgh School of Medicine. Her doctoral thesis focused on the role of renal sodium ion channel transporters in the development of hypertension. She has been published in several peer-reviewed scientific journals and has presented her research at national and international scientific meetings.

Publications
Sonalker PA, Tofovic SP, Bastacky SI, Jackson EK: Chronic noradrenaline increases renal expression of NHE-3, NBC-1, BSC-1 and aquaporin-2,Clinical and Experimental Pharmacology and Physiology, 2008 May; 35: 594-600.

Sonalker PA, Tofovic SP, Jackson EK: Cellular distribution of the renalbumetanide-sensitive Na-K-2Cl cotransporter BSC-1 in the inner stripe of the outer medulla during the development of hypertension in the spontaneously hypertensive rat, Clinical and Experimental Pharmacology and Physiology, 2007 Dec;34(12):1307-12.

Sonalker PA, Jackson EK: Norepinephrine, via beta-Adrenoceptors, Regulates Bumetanide-Sensitive Cotransporter Type 1 Expression in Thick Ascending Limb Cells, Hypertension, 2007 Jun;49(6):1351-7.
Jackson TA, Mi Z, Bastacky SI, McHale T, Melhem MF, Sonalker PA, Tofovic SP, Jackson EK: PPARα agonists improve renal preservation in kidneys subjected to chronic in vitro perfusion: interaction with mannitol, Transplant International. 2007 Mar;20(3):277-90.

Sonalker PA, Tofovic SP, Jackson EK: Increased expression of the sodium transporter BSC-1 in spontaneously hypertensive rats, Journal of Pharmacology and Experimental Therapeutics, 2004 Dec;311(3):1052-61.

Case Highlight

Merck Sharp & Dohme Corp. v. Xellia Pharmaceuticals ApS et al.
D. Del. (2015)

Ruling in favor of our client Merck Sharp & Dohme Corp. ("Merck") and against Defendants Xellia Pharmaceuticals ApS and Xellia Pharmaceuticals, Inc. ("Xellia") concerning infringement of Merck’s patent on Cancidas® covering injectable formulations of caspofungin, a potent antifungal agent used to treat systemic fungal infections.